## Andrew Boulle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6086949/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet, The, 2022, 399, 437-446.	13.7	818
2	Growth patterns of infants with in- utero HIV and ARV exposure in Cape Town, South Africa and Lusaka, Zambia. BMC Public Health, 2022, 22, 55.	2.9	4
3	Attrition from HIV care among youth initiating ART in youthâ€only clinics compared with general primary healthcare clinics in Khayelitsha, South Africa: a matched propensity score analysis. Journal of the International AIDS Society, 2022, 25, e25854.	3.0	4
4	Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections – a survival analysis. International Journal of Infectious Diseases, 2022, 118, 150-154.	3.3	22
5	Determining antenatal medicine exposures in South African women: a comparison of three methods of ascertainment. BMC Pregnancy and Childbirth, 2022, 22, .	2.4	2
6	Cohort profile: the Western Cape Pregnancy Exposure Registry (WCPER). BMJ Open, 2022, 12, e060205.	1.9	2
7	Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clinical Infectious Diseases, 2021, 73, e2005-e2015.	5.8	405
8	High Rates of Recurrent Tuberculosis Disease: A Population-level Cohort Study. Clinical Infectious Diseases, 2021, 72, 1919-1926.	5.8	22
9	Understanding and Responding to Prescribing Patterns of Sodium Valproate-Containing Medicines in Pregnant Women and Women of Childbearing Age in Western Cape, South Africa. Drug Safety, 2021, 44, 41-51.	3.2	6
10	The effects of HIV self-testing on the uptake of HIV testing, linkage to antiretroviral treatment and social harms among adults in Africa: A systematic review and meta-analysis. PLoS ONE, 2021, 16, e0245498.	2.5	18
11	The Impact of Same-Day Antiretroviral Therapy Initiation Under the World Health Organization Treat-All Policy. American Journal of Epidemiology, 2021, 190, 1519-1532.	3.4	22
12	Preterm birth and severe morbidity in hospitalized neonates who are HIV exposed and uninfected compared with HIV unexposed. Aids, 2021, 35, 921-931.	2.2	8
13	Lower birth weight-for-age and length-for-age z-scores in infants with in-utero HIV and ART exposure: a prospective study in Cape Town, South Africa. BMC Pregnancy and Childbirth, 2021, 21, 354.	2.4	16
14	The revolving door of HIV care: Revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals. PLoS Medicine, 2021, 18, e1003651.	8.4	74
15	Early mortality in tuberculosis patients initially lost to follow up following diagnosis in provincial hospitals and primary health care facilities in Western Cape, South Africa. PLoS ONE, 2021, 16, e0252084.	2.5	14
16	Increased infectious-cause hospitalization among infants who are HIV-exposed uninfected compared with HIV-unexposed. Aids, 2021, 35, 2327-2339.	2.2	22
17	Risk factors for COVID-19 hospitalisation and death in people living with diabetes: A virtual cohort study from the Western Cape Province, South Africa. Diabetes Research and Clinical Practice, 2021, 177, 108925.	2.8	12
18	Association between food intake and obesity in pregnant women living with and without HIV in Cape Town, South Africa: a prospective cohort study. BMC Public Health, 2021, 21, 1504.	2.9	6

#	Article	IF	CITATIONS
19	Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. Lancet HIV,the, 2021, 8, e8-e15.	4.7	31
20	Optimised electronic patient records to improve clinical monitoring of HIV-positive patients in rural South Africa (MONART trial): study protocol for a cluster-randomised trial. BMC Infectious Diseases, 2021, 21, 1266.	2.9	4
21	Effect of HIV Infection and Antiretroviral Treatment on Pregnancy Rates in the Western Cape Province of South Africa. Journal of Infectious Diseases, 2020, 221, 1953-1962.	4.0	8
22	Quantifying the HIV treatment cascade in a South African health subâ€district by gender: retrospective cohort study. Tropical Medicine and International Health, 2020, 25, 186-192.	2.3	11
23	Earlier Antiretroviral Therapy Initiation and Decreasing Mortality Among HIV-infected Infants Initiating Antiretroviral Therapy Within 3 Months of Age in South Africa, 2006–2017. Pediatric Infectious Disease Journal, 2020, 39, 127-133.	2.0	17
24	Longâ€ŧerm virologic responses to antiretroviral therapy among HIVâ€positive patients entering adherence clubs in Khayelitsha, Cape Town, South Africa: a longitudinal analysis. Journal of the International AIDS Society, 2020, 23, e25476.	3.0	20
25	Excess mortality associated with mental illness in people living with HIV in Cape Town, South Africa: a cohort study using linked electronic health records. The Lancet Global Health, 2020, 8, e1326-e1334.	6.3	40
26	Consolidating strategic information to monitor progress against the UNAIDS 90–90–90 targets: evaluating the operational feasibility of an electronic HIV testing register in Cape Town, South Africa. BMC Health Services Research, 2020, 20, 720.	2.2	1
27	Changing contextual factors from baseline to 9-months post-HIV diagnosis predict 5-year mortality in Durban, South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 33, 1-8.	1.2	0
28	Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission. PLoS ONE, 2020, 15, e0233693.	2.5	0
29	HIV programmatic outcomes following implementation of the â€~Treatâ€All' policy in a public sector setting in Eswatini: a prospective cohort study. Journal of the International AIDS Society, 2020, 23, e25458.	3.0	12
30	Utility of digitising point of care HIV test results to accurately measure, and improve performance towards, the UNAIDS 90-90-90 targets. PLoS ONE, 2020, 15, e0235471.	2.5	16
31	Populationâ€wide differentials in HIV service access and outcomes in the Western Cape for men as compared to women, South Africa: 2008 to 2018: a cohort analysis. Journal of the International AIDS Society, 2020, 23, e25530.	3.0	32
32	A longitudinal analysis of the completeness of maternal HIV testing, including repeat testing in Cape Town, South Africa. Journal of the International AIDS Society, 2020, 23, e25441.	3.0	6
33	Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data. Clinical Infectious Diseases, 2020, 71, e351-e358.	5.8	23
34	Characterizing the doubleâ€sided cascade of care for adolescents living with HIV transitioning to adulthood across Southern Africa. Journal of the International AIDS Society, 2020, 23, e25447.	3.0	13
35	The Impact of Delayed Switch to Second-Line Antiretroviral Therapy on Mortality, Depending on Definition of Failure Time and CD4 Count at Failure. American Journal of Epidemiology, 2020, 189, 811-819.	3.4	19
36	Outcomes of secondâ€line antiretroviral therapy among children living with HIV: a global cohort analysis. Journal of the International AIDS Society, 2020, 23, e25477.	3.0	5

#	Article	IF	CITATIONS
37	Feasibility of an HIV self-testing intervention: a formative qualitative study among individuals, community leaders, and HIV testing experts in northern Tanzania. BMC Public Health, 2020, 20, 490.	2.9	23
38	Identifying and predicting longitudinal trajectories of care for people newly diagnosed with HIV in South Africa. PLoS ONE, 2020, 15, e0238975.	2.5	6
39	Characteristics and outcomes of adolescents living with perinatally acquired HIV within Southern Africa. Aids, 2020, 34, 2275-2284.	2.2	2
40	Decreased risk of HIVâ€associated TB during antiretroviral therapy expansion in rural Eswatini from 2009 to 2016: a cohort and populationâ€based analysis. Tropical Medicine and International Health, 2019, 24, 1114-1127.	2.3	4
41	A systematic review of qualitative evidence on factors enabling and deterring uptake of HIV self-testing in Africa. BMC Public Health, 2019, 19, 1289.	2.9	93
42	Assessing rates and contextual predictors of 5-year mortality among HIV-infected and HIV-uninfected individuals following HIV testing in Durban, South Africa. BMC Infectious Diseases, 2019, 19, 751.	2.9	4
43	Why South Africa urgently needs to support the development of pregnancy exposure registries. South African Medical Journal, 2019, 109, 294.	0.6	3
44	Stock-outs of antiretroviral and tuberculosis medicines in South Africa: A national cross-sectional survey. PLoS ONE, 2019, 14, e0212405.	2.5	34
45	What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies. Pediatric Infectious Disease Journal, 2019, 38, 400-405.	2.0	4
46	Programmatic outcomes and impact of rapid public sector antiretroviral therapy expansion in adults prior to introduction of the WHO treatâ€all approach in rural Eswatini. Tropical Medicine and International Health, 2019, 24, 701-714.	2.3	18
47	How accurately do routinely reported HIV viral load suppression proportions reflect progress towards the 90-90-90 target in the population on antiretroviral treatment in Khayelitsha, South Africa?. South African Medical Journal, 2019, 109, 174.	0.6	20
48	Trends in maternal and neonatal mortality in South Africa: a systematic review. Systematic Reviews, 2019, 8, 76.	5.3	16
49	Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. Lancet HIV,the, 2019, 6, e105-e115.	4.7	22
50	The effects of add-on corticosteroids on renal outcomes in patients with biopsy proven HIV associated nephropathy: a single centre study from South Africa. BMC Nephrology, 2019, 20, 44.	1.8	6
51	Feasibility of antiretroviral therapy initiation under the treatâ€all policy under routine conditions: a prospective cohort study from Eswatini. Journal of the International AIDS Society, 2019, 22, e25401.	3.0	10
52	Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. Aids, 2019, 33, 525-536.	2.2	7
53	Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study. Clinical Infectious Diseases, 2019, 68, 1522-1529.	5.8	46
54	The Continuing Value of CD4 Cell Count Monitoring for Differential HIV Care and Surveillance. JMIR Public Health and Surveillance, 2019, 5, e11136.	2.6	13

#	Article	IF	CITATIONS
55	Peer Mentorship via Mobile Phones for Newly Diagnosed HIV-Positive Youths in Clinic Care in Khayelitsha, South Africa: Mixed Methods Study. Journal of Medical Internet Research, 2019, 21, e14012.	4.3	17
56	Data Centre Profile: The Provincial Health Data Centre of the Western Cape Province, South Africa. International Journal of Population Data Science, 2019, 4, 1143.	0.1	66
57	Loss to follow-up from antiretroviral therapy clinics: A systematic review and meta-analysis of published studies in South Africa from 2011 to 2015. Southern African Journal of HIV Medicine, 2019, 20, 984.	0.9	12
58	Seasonal variations in tuberculosis diagnosis among HIV-positive individuals in Southern Africa: analysis of cohort studies at antiretroviral treatment programmes. BMJ Open, 2018, 8, e017405.	1.9	5
59	Self-enrolment antenatal health promotion data as an adjunct to maternal clinical information systems in the Western Cape Province of South Africa. BMJ Global Health, 2018, 3, e000565.	4.7	17
60	Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 413-416.	2.1	2
61	Neonatal and infant diagnostic HIV-PCR uptake and associations during three sequential policy periods in Cape Town, South Africa: a longitudinal analysis. Journal of the International AIDS Society, 2018, 21, e25212.	3.0	16
62	Assessing the value of Western Cape Provincial Government health administrative data and electronic pharmacy records in ascertaining medicine use during pregnancy. South African Medical Journal, 2018, 108, 439.	0.6	11
63	Routine data underestimates the incidence of first-line antiretroviral drug discontinuations due to adverse drug reactions: Observational study in two South African cohorts. PLoS ONE, 2018, 13, e0203530.	2.5	3
64	Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia. American Journal of Epidemiology, 2018, 187, 1990-2001.	3.4	8
65	The Continuing Burden of Advanced HIV Disease Over 10 Years of Increasing Antiretroviral Therapy Coverage in South Africa. Clinical Infectious Diseases, 2018, 66, S118-S125.	5.8	93
66	C-reactive protein and procalcitonin to discriminate between tuberculosis, Pneumocystis jirovecii pneumonia, and bacterial pneumonia in HIV-infected inpatients meeting WHO criteria for seriously ill: a prospective cohort study. BMC Infectious Diseases, 2018, 18, 399.	2.9	23
67	Strengthening Routine Data Systems to Track the HIV Epidemic and Guide the Response in Sub-Saharan Africa. JMIR Public Health and Surveillance, 2018, 4, e36.	2.6	22
68	Where do HIVâ€infected adolescents go after transfer? – Tracking transition/transfer of HIVâ€infected adolescents using linkage of cohort data to a health information system platform. Journal of the International AIDS Society, 2017, 20, 21668.	3.0	45
69	Changes in estimated glomerular filtration rate over time in South African HIVâ€1â€infected patients receiving tenofovir: a retrospective cohort study. Journal of the International AIDS Society, 2017, 20, 21317.	3.0	32
70	Twelveâ $\in$ year mortality in adults initiating antiretroviral therapy in South Africa. Journal of the International AIDS Society, 2017, 20, 21902.	3.0	50
71	Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?. Aids, 2017, 31, 147-157.	2.2	12
72	Diagnostic accuracy, incremental yield and prognostic value of Determine TB-LAM for routine diagnostic testing for tuberculosis in HIV-infected patients requiring acute hospital admission in South Africa: a prospective cohort. BMC Medicine, 2017, 15, 67.	5.5	97

#	Article	IF	CITATIONS
73	HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. Journal of the International AIDS Society, 2017, 20, 21327.	3.0	38
74	Contemporary disengagement from antiretroviral therapy in Khayelitsha, South Africa: A cohort study. PLoS Medicine, 2017, 14, e1002407.	8.4	79
75	Trends in maternal and neonatal mortality in South Africa: a systematic review protocol. Systematic Reviews, 2017, 6, 165.	5.3	3
76	High rates of retention and viral suppression in the scaleâ€up of antiretroviral therapy adherence clubs in Cape Town, South Africa. Journal of the International AIDS Society, 2017, 20, 21649.	3.0	88
77	Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: A mathematical modelling study. PLoS Medicine, 2017, 14, e1002468.	8.4	102
78	First-line antiretroviral drug discontinuations in children. PLoS ONE, 2017, 12, e0169762.	2.5	7
79	Predictors of non-adherence to antiretroviral therapy among HIV infected patients in northern Tanzania. PLoS ONE, 2017, 12, e0189460.	2.5	25
80	Feasibility of Establishing HIV Case-Based Surveillance to Measure Progress Along the Health Sector Cascade: Situational Assessments in Tanzania, South Africa, and Kenya. JMIR Public Health and Surveillance, 2017, 3, e44.	2.6	28
81	Pharmacovigilance: A public health priority for South Africa. South African Health Review, 2017, 2017, 125-133.	0.0	3
82	Clinician compliance with laboratory monitoring and prescribing guidelines in HIV-1-infected patients receiving tenofovir. South African Medical Journal, 2016, 106, 369.	0.6	4
83	Life expectancy trends in adults on antiretroviral treatment in South Africa. Aids, 2016, 30, 2545-2550.	2.2	15
84	Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. Aids, 2016, 30, 1279-1286.	2.2	17
85	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, e37-e42.	2.1	27
86	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clinical Infectious Diseases, 2016, 62, 1571-1577.	5.8	52
87	Severe antiretroviralâ€associated skin reactions in South African patients: a case series and case–control analysis. Pharmacoepidemiology and Drug Safety, 2016, 25, 1313-1319.	1.9	18
88	Prospects for HIV control in South Africa: a model-based analysis. Global Health Action, 2016, 9, 30314.	1.9	45
89	The effects of HIV self-testing on the uptake of HIV testing and linkage to antiretroviral treatment among adults in Africa: a systematic review protocol. Systematic Reviews, 2016, 5, 52.	5.3	13
90	Cohort Profile: The Khayelitsha antiretroviral programme, Cape Town, South Africa. International Journal of Epidemiology, 2016, 46, dyw057.	1.9	24

#	Article	IF	CITATIONS
91	Cryptococcal Antigen Screening in Patients Initiating ART in South Africa: A Prospective Cohort Study. Clinical Infectious Diseases, 2016, 62, 581-587.	5.8	99
92	HIV-Related Medical Admissions to a South African District Hospital Remain Frequent Despite Effective Antiretroviral Therapy Scale-Up. Medicine (United States), 2015, 94, e2269.	1.0	60
93	A comparison of death recording by health centres and civil registration in South Africans receiving antiretroviral treatment. Journal of the International AIDS Society, 2015, 18, 20628.	3.0	37
94	Reducing CD4 Monitoring in Children on Antiretroviral Therapy With Virologic Suppression. Pediatric Infectious Disease Journal, 2015, 34, 1361-1364.	2.0	12
95	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, e110-e119.	2.1	8
96	Accounting for and responding to HIV-associated mortality. Aids, 2015, 30, 1.	2.2	5
97	The importance of identified cause-of-death information being available for public health surveillance, actions and research. South African Medical Journal, 2015, 105, 528.	0.6	10
98	Superior virologic and treatment outcomes when viral load is measured at 3 months compared to 6 months on antiretroviral therapy. Journal of the International AIDS Society, 2015, 18, 20092.	3.0	11
99	Temporal trends in TB notification rates during ART scaleâ€up in Cape Town: an ecological analysis. Journal of the International AIDS Society, 2015, 18, 20240.	3.0	21
100	Auditing chronic disease care: Does it make a difference?. African Journal of Primary Health Care and Family Medicine, 2015, 7, .	0.8	10
101	Anemia, Blood Transfusion Requirements and Mortality Risk in Human Immunodeficiency Virus-Infected Adults Requiring Acute Medical Admission to Hospital in South Africa. Open Forum Infectious Diseases, 2015, 2, ofv173.	0.9	12
102	Patterns of HIV, TB, and non-communicable disease multi-morbidity in peri-urban South Africa- a cross sectional study. BMC Infectious Diseases, 2015, 15, 20.	2.9	148
103	Cochrane ColumnImproving people's access to HIV treatmentSummary: Decentralization of HIV care from hospitals to lower levels of careSummary: Task shifting HIV care from doctors to non-doctorsCommentary on task-shiftingCommentary on both decentralization and task-shifting. International Journal of Epidemiology, 2015, 44, 750-755.	1.9	1
104	Age in antiretroviral therapy programmes in South Africa: a retrospective, multicentre, observational cohort study. Lancet HIV,the, 2015, 2, e368-e375.	4.7	29
105	Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 30-38.	1.3	14
106	A threeâ€ŧier framework for monitoring antiretroviral therapy in high HIV burden settings. Journal of the International AIDS Society, 2014, 17, 18908.	3.0	107
107	Immunodeficiency at the Start of Combination Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, e8-e16.	2.1	142
108	Advanced HIV Disease at Antiretroviral Therapy (ART) Initiation Despite Implementation of Expanded ART Eligibility Guidelines During 2007-2012 in Khayelitsha, South Africa. Clinical Infectious Diseases, 2014, 59, 456-457.	5.8	10

#	Article	IF	CITATIONS
109	Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. PLoS Medicine, 2014, 11, e1001718.	8.4	100
110	Patients Lost to Care Are More Likely to be Viremic Than Patients Still in Care. Clinical Infectious Diseases, 2014, 58, 1344-1345.	5.8	13
111	Nonâ€ignorable loss to followâ€up: correcting mortality estimates based on additional outcome ascertainment. Statistics in Medicine, 2014, 33, 129-142.	1.6	36
112	Do Increasing Rates of Loss to Follow-up in Antiretroviral Treatment Programs Imply Deteriorating Patient Retention?. American Journal of Epidemiology, 2014, 180, 1208-1212.	3.4	35
113	Is it safe to drop CD4+ monitoring among virologically suppressed patients. Aids, 2014, 28, 2003-2005.	2.2	20
114	Mortality Among Adults Transferred and Lost to Follow-up From Antiretroviral Therapy Programmes in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, e67-e75.	2.1	47
115	Prognosis of Children With HIV-1 Infection Starting Antiretroviral Therapy in Southern Africa. Pediatric Infectious Disease Journal, 2014, 33, 608-616.	2.0	24
116	Antiretroviral Adherence Interventions in Southern Africa: Implications for Using HIV Treatments for Prevention. Current HIV/AIDS Reports, 2014, 11, 63-71.	3.1	12
117	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	5.8	140
118	A comparison of linkage to HIV care after provider-initiated HIV testing and counselling (PITC) versus voluntary HIV counselling and testing (VCT) for patients with sexually transmitted infections in Cape Town, South Africa. BMC Health Services Research, 2014, 14, 350.	2.2	18
119	Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet, The, 2014, 384, 682-690.	13.7	229
120	Provision of Antiretroviral Therapy in South Africa: The Nuts and Bolts. Antiviral Therapy, 2014, 19, 105-116.	1.0	58
121	Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. International Journal of Tuberculosis and Lung Disease, 2014, 18, 441-448.	1.2	89
122	Impact of definitions of loss to follow-up (LTFU) in antiretroviral therapy program evaluation: variation in the definition can have an appreciable impact on estimated proportions of LTFU. Journal of Clinical Epidemiology, 2013, 66, 1006-1013.	5.0	51
123	Tuberculosis and the risk of opportunistic infections and cancers in <scp>HIV</scp> â€infected patients starting <scp>ART</scp> in Southern Africa. Tropical Medicine and International Health, 2013, 18, 194-198.	2.3	20
124	Immune Recovery After Starting ART in HIV-Infected Patients Presenting and Not Presenting With Tuberculosis in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 142-145.	2.1	21
125	CD4 Count Slope and Mortality in HIV-Infected Patients on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 34-41.	2.1	21
126	Life Expectancies of South African Adults Starting Antiretroviral Treatment: Collaborative Analysis of Cohort Studies. PLoS Medicine, 2013, 10, e1001418.	8.4	330

#	Article	IF	CITATIONS
127	Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa. Antiviral Therapy, 2013, 19, 521-525.	1.0	4
128	Have the explosive HIV epidemics in Sub-Saharan Africa been driven by higher community viral load?. Aids, 2013, 27, 2496-2497.	2.2	3
129	Measles vaccination coverage in high-incidence areas of the Western Cape, following the mass vaccination campaign. South African Medical Journal, 2013, 103, 181.	0.6	4
130	Treatment Response and Mortality among Patients Starting Antiretroviral Therapy with and without Kaposi Sarcoma: A Cohort Study. PLoS ONE, 2013, 8, e64392.	2.5	38
131	Temporal Trends in the Characteristics of Children at Antiretroviral Therapy Initiation in Southern Africa: The IeDEA-SA Collaboration. PLoS ONE, 2013, 8, e81037.	2.5	36
132	Effectiveness of Patient Adherence Groups as a Model of Care for Stable Patients on Antiretroviral Therapy in Khayelitsha, Cape Town, South Africa. PLoS ONE, 2013, 8, e56088.	2.5	172
133	Monitoring of Antiretroviral Therapy and Mortality in HIV Programmes in Malawi, South Africa and Zambia: Mathematical Modelling Study. PLoS ONE, 2013, 8, e57611.	2.5	27
134	High rate of virological re-suppression among patients failing second-line antiretroviral therapy following enhanced adherence support: A model of care in Khayelitsha, South Africa. Southern African Journal of HIV Medicine, 2013, 14, 170.	0.9	5
135	Estimated mortality of adult HIV-infected patients starting treatment with combination antiretroviral therapy. Sexually Transmitted Infections, 2012, 88, i33-i43.	1.9	52
136	Cohort Profile: The international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. International Journal of Epidemiology, 2012, 41, 1256-1264.	1.9	224
137	Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. European Respiratory Journal, 2012, 39, 163-171.	6.7	26
138	Effect of Antiretroviral Therapy on the Diagnostic Accuracy of Symptom Screening for Intensified Tuberculosis Case Finding in a South African HIV Clinic. Clinical Infectious Diseases, 2012, 55, 1698-1706.	5.8	48
139	Immune reconstitution inflammatory syndrome in a large multicenter cohort study: case definition and comparability. Expert Review of Anti-Infective Therapy, 2012, 10, 737-741.	4.4	7
140	The spectrum of renal histologies seen in HIV with outcomes, prognostic indicators and clinical correlations. Nephrology Dialysis Transplantation, 2012, 27, 4109-4118.	0.7	90
141	Coverage of the Prevention of Mother-to-Child Transmission Program in the Western Cape, South Africa Using Cord Blood Surveillance. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 199-204.	2.1	13
142	Rates and Predictors of Failure of First-line Antiretroviral Therapy and Switch to Second-line ART in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 428-437.	2.1	119
143	Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings. Aids, 2012, 26, 929-938.	2.2	151
144	Viral load monitoring of antiretroviral therapy, cohort viral load and HIV transmission in Southern Africa. Aids, 2012, 26, 1403-1413.	2.2	30

#	Article	IF	CITATIONS
145	The causal effect of switching to second-line ART in programmes without access to routine viral load monitoring. Aids, 2012, 26, 57-65.	2.2	39
146	Tenofovir in Second-Line ART in Zambia and South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 41-48.	2.1	12
147	The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure. Tropical Medicine and International Health, 2012, 17, 1386-1390.	2.3	9
148	Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet, The, 2012, 380, 889-898.	13.7	243
149	A Tale Of Two Epidemics Within TWO Countries. Journal of Adolescent Health, 2012, 50, 208-209.	2.5	1
150	High yield of culture-based diagnosis in a TB-endemic setting. BMC Infectious Diseases, 2012, 12, 218.	2.9	10
151	Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings. BMC Infectious Diseases, 2012, 12, 147.	2.9	7
152	The Effect of Complete Integration of HIV and TB Services on Time to Initiation of Antiretroviral Therapy: A Before-After Study. PLoS ONE, 2012, 7, e46988.	2.5	48
153	Shortâ€ŧerm risk of anaemia following initiation of combination antiretroviral treatment in HIVâ€infected patients in countries in sub‧aharan Africa, Asiaâ€Pacific, and central and South America. Journal of the International AIDS Society, 2012, 15, 5-5.	3.0	34
154	Elevation and cholera: an epidemiological spatial analysis of the cholera epidemic in Harare, Zimbabwe, 2008-2009. BMC Public Health, 2012, 12, 442.	2.9	33
155	Gender Differences in Survival among Adult Patients Starting Antiretroviral Therapy in South Africa: A Multicentre Cohort Study. PLoS Medicine, 2012, 9, e1001304.	8.4	199
156	Guidelines for antiretroviral therapy in adults. Southern African Journal of HIV Medicine, 2012, 13, .	0.9	12
157	Virologic Failure and Second-Line Antiretroviral Therapy in Children in South Africa—The IeDEA Southern Africa Collaboration. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 270-278.	2.1	112
158	Retention Among Adults Initiating Antiretroviral Therapy in South Africa: 2002–2007. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e102.	2.1	0
159	Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. International Journal of Tuberculosis and Lung Disease, 2011, 15, 620-627.	1.2	34
160	In reply to â€ <sup>~</sup> Pre-screening with GeneXpert® MTB/RIF may increase use of isoniazid preventive therapy in antiretroviral programmes' [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1273-1274.	1.2	1
161	Time to Initiation of Antiretroviral Therapy Among Patients With HIV-Associated Tuberculosis in Cape Town, South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 57, 136-140.	2.1	34
162	Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy – The IeDEA Southern Africa Collaboration. Tropical Medicine and International Health, 2011, 16, 1367-1371.	2.3	21

#	Article	IF	CITATIONS
163	Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa. Aids, 2011, 25, 1761-1769.	2.2	98
164	Correcting for Mortality Among Patients Lost to Follow Up on Antiretroviral Therapy in South Africa: A Cohort Analysis. PLoS ONE, 2011, 6, e14684.	2.5	81
165	Estimating Loss to Follow-Up in HIV-Infected Patients on Antiretroviral Therapy: The Effect of the Competing Risk of Death in Zambia and Switzerland. PLoS ONE, 2011, 6, e27919.	2.5	54
166	How should access to antiretroviral treatment be measured?. Bulletin of the World Health Organization, 2011, 89, 157-160.	3.3	10
167	Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. Aids, 2010, 24, 563-572.	2.2	237
168	Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002–2007. Aids, 2010, 24, 2263-2270.	2.2	198
169	Reduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme: a retrospective observational study. AIDS Research and Therapy, 2010, 7, 13.	1.7	2
170	AIDSâ€associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa. Journal of the International AIDS Society, 2010, 13, 23-23.	3.0	51
171	Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case–control study. HIV Medicine, 2010, 11, 121-129.	2.2	30
172	Mortality after failure of antiretroviral therapy in sub‣aharan Africa. Tropical Medicine and International Health, 2010, 15, 251-258.	2.3	71
173	Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa. Tropical Medicine and International Health, 2010, 15, 825-832.	2.3	68
174	ORIGINAL ARTICLE: Autoimmunity predominates in a large South African cohort with addison's disease of mainly European descent despite longâ€standing disease and is associated with HLA DQB*0201. Clinical Endocrinology, 2010, 73, 291-298.	2.4	23
175	Prolonged deferral of antiretroviral therapy in the SAPIT trial: Did we need a clinical trial to tell us that this would increase mortality?. South African Medical Journal, 2010, 100, 566.	0.6	11
176	Orphans of the AIDS epidemic? The extent, nature and circumstances of child-headed households in South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 40-49.	1.2	57
177	Influence of human immunodeficiency virus and CD4 count on the prevalence of human papillomavirus in heterosexual couples. Journal of General Virology, 2010, 91, 3023-3031.	2.9	37
178	Associations With Virologic Treatment Failure in Adults on Antiretroviral Therapy in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 489-495.	2.1	34
179	Central nervous system disorders after starting antiretroviral therapy in South Africa. Aids, 2010, 24, 2871-2876.	2.2	60
180	Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet, The, 2010, 376, 449-457.	13.7	203

#	Article	IF	CITATIONS
181	"l don't use a condom (with my regular partner) because I know that I'm faithful, but with everyone else I doâ€ŧ The cultural and socioeconomic determinants of sexual partner concurrency in young South Africans. Sahara J, 2010, 7, 35-43.	0.7	33
182	Nevirapine-Associated Early Hepatotoxicity: Incidence, Risk Factors, and Associated Mortality in a Primary Care ART Programme in South Africa. PLoS ONE, 2010, 5, e9183.	2.5	36
183	Early Adherence to Antiretroviral Medication as a Predictor of Long-Term HIV Virological Suppression: Five-Year Follow Up of an Observational Cohort. PLoS ONE, 2010, 5, e10460.	2.5	79
184	Adjusting Mortality for Loss to Follow-Up: Analysis of Five ART Programmes in Sub-Saharan Africa. PLoS ONE, 2010, 5, e14149.	2.5	85
185	Efavirenz in pregnancy. Southern African Journal of HIV Medicine, 2010, 11, .	0.9	1
186	Commentary: Reducing HIV-associated tuberculosis in children. International Journal of Epidemiology, 2009, 38, 1621-1623.	1.9	1
187	Mortality of HIV-Infected Patients Starting Antiretroviral Therapy in Sub-Saharan Africa: Comparison with HIV-Unrelated Mortality. PLoS Medicine, 2009, 6, e1000066.	8.4	161
188	Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Tropical Medicine and International Health, 2009, 14, 1220-1225.	2.3	78
189	A network-level explanation for the differences in HIV prevalence in South Africa's racial groups. African Journal of AIDS Research, 2009, 8, 243-254.	0.9	38
190	Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial. Malaria Journal, 2009, 8, 141.	2.3	14
191	Paediatric antiretroviral treatment programmes in sub-Saharan Africa: a review of published clinical studies. African Journal of AIDS Research, 2009, 8, 329-338.	0.9	18
192	High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. Aids, 2009, 23, 1182-1183.	2.2	83
193	Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. Aids, 2009, 23, 1867-1874.	2.2	136
194	Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration. South African Medical Journal, 2009, 99, 653-60.	0.6	44
195	Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. South African Medical Journal, 2009, 99, 730-7.	0.6	93
196	Streamlining tasks and roles to expand treatment and care for HIV: randomised controlled trial protocol. Trials, 2008, 9, 21.	1.6	23
197	Provision of antiretroviral therapy to children within the public sector of South Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, 905-911.	1.8	25
198	Antiretroviral therapy in resourceâ€limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in subâ€saharan Africa, Asia and Latin America. Tropical Medicine and International Health, 2008, 13, 870-879.	2.3	162

#	Article	IF	CITATIONS
199	Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatrics, 2008, 8, 34.	1.7	82
200	Population effect of scaling up ART in resource-poor settings. Lancet, The, 2008, 371, 1558-1559.	13.7	17
201	THE BURDEN OF HIV/AIDS IN THE PUBLIC HEALTHCARE SYSTEM. South African Journal of Economics, 2008, 76, S3.	2.2	18
202	Low Risk of Death, but Substantial Program Attrition, in Pediatric HIV Treatment Cohorts in Sub-Saharan Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 523-531.	2.1	106
203	Outcomes of Nevirapine- and Efavirenz-Based Antiretroviral Therapy When Coadministered With Rifampicin-Based Antitubercular Therapy. JAMA - Journal of the American Medical Association, 2008, 300, 530.	7.4	170
204	Eearly loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bulletin of the World Health Organization, 2008, 86, 559-567.	3.3	275
205	Monitoring effectiveness of programmes to prevent mother-to-child HIV transmission in lower-income countries. Bulletin of the World Health Organization, 2008, 86, 57-62.	3.3	112
206	Effectiveness of Antiretroviral Treatment in a South African Program <subtitle>A Cohort Study</subtitle> . Archives of Internal Medicine, 2008, 168, 86.	3.8	160
207	Scaling up antiretroviral therapy in developing countries: what are the benefits and challenges?. Postgraduate Medical Journal, 2008, 84, 225-227.	1.8	15
208	Exploring HIV risk perception and behaviour in the context of antiretroviral treatment: results from a township household survey. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2008, 20, 771-781.	1.2	18
209	Antiretroviral therapy and early mortality in South Africa. Bulletin of the World Health Organization, 2008, 86, 678-687.	3.3	131
210	Cohort Profile: The Paediatric Antiretroviral Treatment Programmes in Lower-Income Countries (KIDS-ART-LINC) Collaboration. International Journal of Epidemiology, 2008, 37, 474-480.	1.9	30
211	Gender and the Use of Antiretroviral Treatment in Resource-Constrained Settings: Findings from a Multicenter Collaboration. Journal of Women's Health, 2008, 17, 47-55.	3.3	178
212	Two-Year Outcomes of Children on Non-Nucleoside Reverse Transcriptase Inhibitor and Protease Inhibitor Regimens in a South African Pediatric Antiretroviral Program. Pediatric Infectious Disease Journal, 2008, 27, 993-998.	2.0	45
213	Public-Health and Individual Approaches to Antiretroviral Therapy: Township South Africa and Switzerland Compared. PLoS Medicine, 2008, 5, e148.	8.4	113
214	Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings. Bulletin of the World Health Organization, 2008, 86, 939-947.	3.3	139
215	Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa. Antiviral Therapy, 2008, 13, 937-43.	1.0	7
216	Severe Hyperlactataemia Complicating Stavudine First-Line Antiretroviral Therapy in South Africa. Antiviral Therapy, 2008, 13, 937-943.	1.0	10

#	Article	IF	CITATIONS
217	Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. Journal of Antimicrobial Chemotherapy, 2007, 61, 389-393.	3.0	72
218	Tuberculosis after Initiation of Antiretroviral Therapy in Low-Income and High-Income Countries. Clinical Infectious Diseases, 2007, 45, 1518-1521.	5.8	98
219	Commentary: Factors affecting HIV/AIDS-related stigma and discrimination by medical professionals. International Journal of Epidemiology, 2007, 36, 185-186.	1.9	34
220	CD4 T-cell responses to combination antiretroviral therapy. Lancet, The, 2007, 370, 366-368.	13.7	7
221	Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antiviral Therapy, 2007, 12, 753-60.	1.0	67
222	Substitutions Due to Antiretroviral Toxicity or Contraindication in the First 3 years of Antiretroviral Therapy in a Large South African Cohort. Antiviral Therapy, 2007, 12, 753-760.	1.0	115
223	Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet, The, 2006, 367, 817-824.	13.7	1,030
224	The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africaa primary data analysis. Cost Effectiveness and Resource Allocation, 2006, 4, 20.	1.5	109
225	Antiretroviral therapy in resource-poor settings: scaling up inequalities?. International Journal of Epidemiology, 2005, 34, 509-512.	1.9	27
226	Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. International Journal of Epidemiology, 2005, 34, 979-986.	1.9	72
227	Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa. Bulletin of the World Health Organization, 2005, 83, 489-94.	3.3	44
228	Promoting adherence to antiretroviral therapy. Aids, 2004, 18, S27-S31.	2.2	119
229	Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. Aids, 2004, 18, 887-895.	2.2	475
230	The Nervous System Effects of Occupational Exposure on Workers in a South African Manganese Smelter. NeuroToxicology, 2003, 24, 885-894.	3.0	90
231	Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa. South African Medical Journal, 2002, 92, 811-7.	0.6	14
232	A case study of using artificial neural networks for classifying cause of death from verbal autopsy. International Journal of Epidemiology, 2001, 30, 515-520.	1.9	39